Omitting Biopsy With Negative MRI Reduces Detection of Clinically Insignificant Prostate Cancer
By Elana Gotkine HealthDay Reporter
FRIDAY, Sept. 27, 2024 -- Omitting biopsy in patients with negative magnetic resonance imaging (MRI) results is associated with a significantly reduced relative risk for detecting clinically insignificant prostate cancer, according to a study published in the Sept. 26 issue of the New England Journal of Medicine.
Jonas Hugosson, M.D., Ph.D., from Sahlgrenska Academy at the University of Gothenburg in Sweden, and colleagues invited men aged 50 to 60 years to undergo prostate-specific antigen (PSA) screening in a population-based trial that started in 2015. Men with a PSA of 3 ng/mL or higher underwent MRI of the prostate. Men were randomly assigned to the systematic biopsy group, in which they underwent systematic biopsy or targeted biopsy in the case of suspicious lesions on MRI, or to targeted biopsy only. Depending on the PSA level, men were invited for repeat screening two, four, or eight years later.
After a median follow-up of 3.9 years, the researchers found that prostate cancer was detected in 185 of the 6,575 men (2.8 percent) in the MRI-targeted biopsy group and in 298 of the 6,578 men (4.5 percent) in the systematic biopsy group. Detecting clinically insignificant cancer in the MRI-targeted biopsy group versus the systematic biopsy group had a relative risk of 0.43 (95 percent confidence interval, 0.32 to 0.57) and was lower at repeat rounds of screening (relative risk, 0.25 versus 0.49). For a diagnosis of clinically significant prostate cancer, the relative risk was 0.84 (95 percent confidence interval, 0.66 to 1.07).
"These results should encourage guideline committees to update recommendations around prostate cancer diagnosis and screening," the authors write.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2024
Read this next
ASTRO: Intensity-Modulated RT, Proton Beam Therapy Have Similar Outcomes in Prostate Cancer
FRIDAY, Oct. 4, 2024 -- Intensity-modulated radiation therapy (IMRT) and proton beam therapy (PBT) offer similar outcomes for patients with localized prostate cancer, according to...
GLP-1 RA Use Linked to Retained Gastric Contents During Endoscopies
FRIDAY, Oct. 4, 2024 -- Use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is associated with the risk for retained gastric contents and inadequate bowel preparation...
No Infections Seen After Transperineal Biopsy for Prostate Cancer
MONDAY, Sept. 30, 2024 -- For patients with suspicion for prostate cancer, transperineal biopsy has similar cancer detection rates as transrectal biopsy but a significantly lower...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.